Royal Bank Of Canada Aldeyra Therapeutics, Inc. Transaction History
Royal Bank Of Canada
- $471 Billion
- Q3 2024
A detailed history of Royal Bank Of Canada transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,871 shares of ALDX stock, worth $24,647. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,871
Previous 4,686
3.95%
Holding current value
$24,647
Previous $15,000
73.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$46.9 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$27.7 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$19 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.3 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$9.52 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $295M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...